These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

949 related articles for article (PubMed ID: 10634385)

  • 21. The GHRH/GHRP-6 test for the diagnosis of GH deficiency in elderly or severely obese men.
    Haijma SV; van Dam PS; de Vries WR; Maitimu-Smeele I; Dieguez C; Casanueva FF; Koppeschaar HP
    Eur J Endocrinol; 2005 Apr; 152(4):575-80. PubMed ID: 15817913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.
    Veldhuis JD; Bidlingmaier M; Anderson SM; Wu Z; Strasburger CJ
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3304-10. PubMed ID: 11443205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gender and sexual maturation-dependent contrasts in the neuroregulation of growth hormone secretion in prepubertal and late adolescent males and females--a general clinical research center-based study.
    Veldhuis JD; Roemmich JN; Rogol AD
    J Clin Endocrinol Metab; 2000 Jul; 85(7):2385-94. PubMed ID: 10902783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth hormone (GH) response to GH-releasing peptide-6 in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion.
    Catalina PF; Mallo F; Andrade MA; García-Mayor RV; Diéguez C
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3663-7. PubMed ID: 9768681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness.
    Van den Berghe G; Wouters P; Bowers CY; de Zegher F; Bouillon R; Veldhuis JD
    Eur J Endocrinol; 1999 Jan; 140(1):17-22. PubMed ID: 10037246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency.
    Thorén M; Hilding A; Baxter RC; Degerblad M; Wivall-Helleryd IL; Hall K
    J Clin Endocrinol Metab; 1997 Jan; 82(1):223-8. PubMed ID: 8989263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.
    Arosio M; Garrone S; Bruzzi P; Faglia G; Minuto F; Barreca A
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1091-8. PubMed ID: 11238491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.
    Bowers CY; Granda-Ayala R
    Endocrine; 2001 Feb; 14(1):79-86. PubMed ID: 11322505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of cranial irradiation on GH responsiveness to GHRH plus GH-releasing peptide-6.
    Popovic V; Pekic S; Golubicic I; Doknic M; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 2002 May; 87(5):2095-9. PubMed ID: 11994347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel relationships of age, visceral adiposity, insulin-like growth factor (IGF)-I and IGF binding protein concentrations to growth hormone (GH) releasing-hormone and GH releasing-peptide efficacies in men during experimental hypogonadal clamp.
    Veldhuis JD; Keenan DM; Bailey JN; Adeniji AM; Miles JM; Bowers CY
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2137-43. PubMed ID: 19351723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of androgen administration on the growth hormone-insulin-like growth factor I axis in men with acquired immunodeficiency syndrome wasting.
    Grinspoon S; Corcoran C; Stanley T; Katznelson L; Klibanski A
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4251-6. PubMed ID: 9851759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
    Marzullo P; Di Somma C; Pratt KL; Khosravi J; Diamandis A; Lombardi G; Colao A; Rosenfeld RG
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
    Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
    J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preservation of GHRH and GH-releasing peptide-2 efficacy in young men with experimentally induced hypogonadism.
    Veldhuis JD; Keenan DM; Bailey JN; Miles JM; Bowers CY
    Eur J Endocrinol; 2009 Aug; 161(2):293-300. PubMed ID: 19458139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1-44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in postmenopausal women equally in the estrogen-withdrawn and estrogen-supplemented states.
    Evans WS; Anderson SM; Hull LT; Azimi PP; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Feb; 86(2):700-12. PubMed ID: 11158034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men.
    Münzer T; Rosen CJ; Harman SM; Pabst KM; St Clair C; Sorkin JD; Blackman MR
    Am J Physiol Endocrinol Metab; 2006 May; 290(5):E1006-13. PubMed ID: 16390864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential impact of simple childhood obesity on the components of the growth hormone-insulin-like growth factor (IGF)-IGF binding proteins axis.
    Ballerini MG; Ropelato MG; Domené HM; Pennisi P; Heinrich JJ; Jasper HG
    J Pediatr Endocrinol Metab; 2004 May; 17(5):749-57. PubMed ID: 15237710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accelerated escape from GH autonegative feedback in midpuberty in males: evidence for time-delimited GH-induced somatostatinergic outflow in adolescent boys.
    Richmond E; Rogol AD; Basdemir D; Veldhuis OL; Clarke W; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3837-44. PubMed ID: 12161519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures.
    Benbassat CA; Maki KC; Unterman TG
    J Clin Endocrinol Metab; 1997 May; 82(5):1484-91. PubMed ID: 9141538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. E2 supplementation selectively relieves GH's autonegative feedback on GH-releasing peptide-2-stimulated GH secretion.
    Anderson SM; Wideman L; Patrie JT; Weltman A; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5904-11. PubMed ID: 11739462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.